Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Coronavirus COVID-19 Vaccines Regulation

Coronavirus Notebook: WHO Backs Actemra & Kevzara In COVID-19, German Body Says Remdesivir Has ‘Considerable Added Benefit’

  • News

Executive Summary

The UK REACT-1 study has shown a threefold reduction in COVID-19 infections in double-vaccinated adults.

You may also be interested in...



EU Assessing Roche’s RoActemra For Hospitalized COVID-19 Patients

Three authorized products currently used for arthritis and other conditions have now been filed for approval in Europe for treating people with severe COVID-19.

Roche Under Fire Over ‘Unaffordable’ COVID-19 Therapy Actemra

The World Health Organization has taken the unusual step of calling for lower drug prices to help COVID-19 patients access IL-6 therapies in developing nations.

EU Could Soon Have Three XBB.1.5 COVID-19 Vaccines For Winter Season

The head of the European Medicines Agency says a group of international regulators got together to ensure “global alignment” on the approach to be taken on COVID-19 vaccination. 

Table

View full table

Topics

Related Companies

Tags:
Coronavirus COVID-19 Vaccines Regulation
Latest Headlines

Finding The Sweet Spot For Real-World Evidence: Aetion Stresses Early Feasibility Assessment

FDA Gene Therapy Office Chief Prefers Flexibility With Accelerated Approval Confirmatory Trials

Keeping Track: Return & Renewal At US FDA

Korean Bioclusters Offer Tax, Other Incentives To Attract Global Firms, Talent

See All
UsernamePublicRestriction

Register

PS144603

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By